Protagonist Therapeutics shares are trading higher after Truist Securities initiated coverage on the stock with a Buy rating and announced a price target of $60.
Portfolio Pulse from Benzinga Newsdesk
Protagonist Therapeutics shares rose after Truist Securities initiated coverage with a Buy rating and set a price target of $60.
September 09, 2024 | 5:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Protagonist Therapeutics shares increased following Truist Securities' initiation of coverage with a Buy rating and a $60 price target.
The initiation of coverage by Truist Securities with a Buy rating and a $60 price target is a positive signal to investors, likely boosting investor confidence and driving the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100